Pharmaceutical Research and Manufacturers of America. PhRMA code on interactions with healthcare professionals. Washington, DC; 2008.
Harris G. Drug industry to announce revised code on marketing. New York Times 2008 July 10.
Physicians and the pharmaceutical industry - Is a gift ever just a gift? JAMA. 2000;283:373–80.CrossRefPubMed
Is your doctor tied to drug makers? New York Times 2007 Jul 2.
Harris G. Senators seek public listing of payments to doctors. New York Times 2007 Sep 7.
Waxman HA. Memorandum: The marketing of Vioxx to physicians. Washington, DC: United States House of Representatives - Committee on Government Reform; 2005.
The lessons of Vioxx: drug safety and sales. N Engl J Med. 2005;352:2576–8.CrossRefPubMed
Meier B, Saul S. Marketing of Vioxx: how Merck played game of catch-up. New York Times 2005 February 11.
Gagnon M, Lexchin J.
The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine. 2008;5:29–33.CrossRef
Pharmaceutical marketing research and the prescribing physician. Ann Intern Med. 2007;146:742–48.PubMed
Opinion of the Council on Ethical and Judicial Affairs E-8.061: gifts to physicians from industry. American Medical Association. (Accessed April 30, 2009, at http://www.ama-assn.org/ama1/pub/upload/mm/Code_of_Med_Eth/opinion/opinion8061.html
PhRMA code on interactions with healthcare professionals. 2002. (Accessed April 30, 2009, at http://www.phrma.org/files/PhRMA%20Code.pdf
Opinion E-8.061 Gifts to Physicians from Industry: clarifying addendum. American Medical Association. (Accessed April 30, 2008, at http://www.ama-assn.org/ama1/pub/upload/mm/Code_of_Med_Eth/opinion/opinion8061.html
Brennan TA, Rothman DJ, Blank L,et al
. Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. JAMA. 2006;295:429–33.CrossRefPubMed
Association of American Medical Colleges. Industry funding of medical education - report of an AAMC task force. Washington, DC; 2008.
AMSA PharmFree Scorecard. American Medical Student Association, 2008. (Accessed April 30, 2009, at http://amsascorecard.org/
Campbell E, Gruen R, Mountford J, Miller L, Clearly P, Blumenthal D.
A national survey of physician-industry relationships. N Engl J Med. 2007;356:1742–50.CrossRefPubMed
Gibbons R, Landry F, Blouch D, et al
. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. J Gen Intern Med. 1998;13:151–54.CrossRefPubMed
Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM.
Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA. 2007;297:1216–23.CrossRefPubMed
Dana J, Loewenstein G.
A social science perspective on gifts to physicians from industry. JAMA. 2003;290:252–55.CrossRefPubMed
Department of Health and Human Services - Office of the Inspector General. OIG compliance program guidance for pharmaceutical manufacturers. Fed Regist. 2003;68:23731–43.
Chimonas S, Rothman DJ.
New federal guidelines for physician-pharmaceutical industry relations: The politics of policy formation. Health Aff. 2005;24:949–60.CrossRef
Studdert D, Mello M, Brennan TA.
Financial conflicts of interest in physicians' relationships with the pharmaceutical industry - Self-regulation in the shadow of federal prosecution. N Engl J Med. 2004;351:1891–900.CrossRefPubMed
§ 151.47. In: Minnesota Statutes; 2006.
§ 4632. In: Vermont Statutes; 2007.
An Act to Promote Cost Containment, Transparency, and Efficiency in the Delivery of Quality Health Care. General Laws of Massachusetts; 2008.
Payments to physicians fact sheet. The Prescription Project. (Accessed April 10, 2009, at http://prescriptionproject.org/tools/solutions_factsheets/files/0006.pdf
Physician Payments Sunshine Act of 2007 - S. 2029. Library of Congress. (Accessed April 30, 2009, at http://thomas.loc.gov/
O'Reilly K. "Sunshine" bill sets $100 trigger for disclosing drug industry pay to doctors. AMNews 2009 Feb 23.
O'Reilly K. Drugmakers vow to disclose their payments to physicians. AMNews 2008 Nov 17.
Cain D, Loewenstein G, Moore D.
The dirt on coming clean: perverse effects of disclosing conflicts of interest. J Legal Stud. 2005;34:1–25.CrossRef
Harris G. Doctors' ties to drug makers are put on close view. New York Times 2007 March 21.
Harris G. 3 Researchers at Harvard are Named in Subpoena. New York Times 2009 March 27.
Harris G. Psychiatrists Top List in Drug Maker Gifts. New York Times 2007 June 22.
§ 151.461. In: Minnesota Statutes; 2006.
CMR 970.000: Pharmaceutical and Medical Device Manufacturer Conduct. 2009. (Accessed April 30, 2009, at http://www.mass.gov/Eeohhs2/docs/dph/regs/105cmr970.pdf
Harris G. Minnesota limits on gifts to doctors may catch on. New York Times 2007 October 12.
Aitken M, Berndt ER, Cutler DM. Prescription drug spending trends in the United States: Looking beyond the turning point. Health Aff 2009;28:w151–60.
Prescription Information Law. In: NH Rev Stat Ann; 2006.
DataMonitor. Personalized physician marketing: Using physician profiling to maximize returns. New York, NY; 2001.
IMS Health Inc. and Verispan, LLC v. Kelly A. Ayotte, New Hampshire Attorney General. 2008. (Accessed April 30, 2009, at http://www.ca1.uscourts.gov/pdf.opinions/07-1945P-01A.pdf
Prescription Data Restriction Program. American Medical Association. (Accessed April 30, 2009, at http://www.ama-assn.org/ama/no-index/about-ama/12054.shtml
Grande D, Asch DA.
Commercial versus social goals of tracking what doctors do. N Engl J Med. 2009;360:747–9.CrossRefPubMed
DC ST § 3-1202.08, 3-1207.42, 3-1207.41. In: District of Columbia Code; 2008 (June 4).
Independent Drug Information Service. (Accessed April 30, 2009, at http://www.rxfacts.org/
Under the Influence: Can We Provide Doctors An Alternative To Biased Drug Reviews? United State Senate Special Committee on Aging, 2008. (Accessed April 30, 2009, at http://aging.senate.gov/hearing_detail.cfm?id=301126&
O’Brien M, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007;4:Art. No.: CD000409.
Katz P. These drug reps come bearing facts, not freebies. ACP Observer 2007 July-August.
Industry-to-physician marketing and the cost of prescription drugs. Am J Bioeth. 2003;3:W28–9.PubMed
Statehealthfacts.org: Pennsylvania providers and service use. 2007. (Accessed April 30, 2008, at http://statehealthfacts.org/profileind.jsp?cat=8&sub=100&rgn=40
Rothman DJ, McDonald WJ, Berkowitz CD, et al
. Professional medical associations and their relationships with industry: A proposal for controlling conflict of interest. JAMA. 2009;301:1367–72.CrossRefPubMed